How should I manage a 55-year-old woman with severe hyperglycemia (HbA1c 13.7%), impaired renal function (eGFR 32 mL/min/1.73 m²), alkaline phosphatase 148 U/L, magnesium 2.7 mg/dL, sodium 134 mmol/L, potassium 5.0 mmol/L, phosphorus 3.6 mg/dL, GGT 31 U/L, and blood pressure 142/78 mmHg who is currently taking dapagliflozin (Farxiga) 10 mg daily?

Management of Severe Hyperglycemia with Advanced CKD on Dapagliflozin

Continue dapagliflozin 10 mg daily and immediately add a GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide) plus initiate an ACE inhibitor or ARB for blood pressure control and renal protection. 1, 2

Immediate Actions Required

1. Continue SGLT2 Inhibitor Therapy

• Keep dapagliflozin at 10 mg daily despite the eGFR of 32 mL/min/1.73 m². The 2025 ADA guidelines explicitly state SGLT2 inhibitors should be used down to eGFR ≥20 mL/min/1.73 m² for cardiovascular and kidney protection 2. The 2022 ADA/KDIGO consensus confirms dapagliflozin can be initiated and continued at 10 mg daily with eGFR 25-44 mL/min/1.73 m² 1.
• While glucose-lowering efficacy diminishes at this eGFR level 3, 4, the cardiovascular and kidney protective benefits remain robust 2.
• The DAPA-CKD trial demonstrated a 61% risk reduction in kidney disease progression in patients with similar eGFR levels 2.

2. Add GLP-1 Receptor Agonist Immediately

This is the critical missing medication. With an A1c of 13.7%, monotherapy is grossly inadequate 1, 2.

• Preferred agents: Dulaglutide, liraglutide, or semaglutide (all require no dose adjustment at eGFR 32) 1
• These agents provide:
  • Substantial A1c reduction (expect 1.5-2% decrease) 5
  • Cardiovascular protection (20-31% reduction in MACE) 1
  • Kidney protection (22-36% reduction in nephropathy progression) 2
  • Weight loss benefit
• Avoid exenatide at this eGFR level 1

3. Initiate Blood Pressure Control

Blood pressure of 142/78 mmHg requires treatment, especially with CKD stage 3b.

• Start an ACE inhibitor or ARB (if not already on one—this information is missing from the case)
• Target BP <130/80 mmHg in patients with diabetes and CKD
• The potassium of 5.0 mmol/L is acceptable and not a contraindication 6. Dapagliflozin does not increase hyperkalemia risk even with concurrent ACE/ARB use 6.
• Dapagliflozin will provide modest additional BP reduction (3.2 mmHg systolic, 1.0 mmHg diastolic) 7

4. Consider Adding Basal Insulin

With A1c 13.7%, dual therapy may still be insufficient.

• Add basal insulin (e.g., glargine or degludec) starting at conservative doses (0.1-0.15 units/kg/day)
• Titrate cautiously given eGFR 32—increased hypoglycemia risk with renal impairment 1
• The combination of SGLT2i + GLP-1 RA + basal insulin is highly effective for severe hyperglycemia 5

Critical Safety Considerations

Volume Status and Ketoacidosis Risk

• Assess volume status before each medication adjustment 8
• The sodium of 134 mmol/L suggests possible volume depletion—correct this before intensifying therapy
• Educate patient on diabetic ketoacidosis (DKA) symptoms and instruct to discontinue dapagliflozin if signs occur 8
• Withhold dapagliflozin 3 days before any major surgery or prolonged fasting 8

Hypoglycemia Prevention

• When adding GLP-1 RA and insulin, start with conservative doses
• GLP-1 RAs reduce hypoglycemia risk compared to insulin alone
• Monitor closely during titration phase

Monitoring Parameters

• Renal function: Check eGFR and electrolytes in 2-4 weeks after medication changes 8
• A1c: Recheck in 3 months (expect reduction to 9-10% range initially)
• Blood pressure: Weekly home monitoring
• Urinary tract infections: SGLT2 inhibitors increase UTI risk—educate on symptoms 8
• Genital mycotic infections: More common in women on SGLT2 inhibitors 1, 8

Laboratory Abnormalities to Address

Elevated Alkaline Phosphatase (148 U/L)

• Mildly elevated; likely related to diabetes/metabolic syndrome
• GGT is normal (31 U/L), making hepatobiliary disease less likely
• Recheck in 3 months; no immediate intervention needed

Mild Hyponatremia (134 mmol/L)

• Assess volume status clinically
• May improve with better glycemic control (osmotic diuresis from severe hyperglycemia)
• If volume depleted, hold dapagliflozin temporarily until corrected 8

Elevated Magnesium (2.7 mg/dL)

• Slightly above normal; common with CKD
• No intervention needed unless symptomatic
• Monitor with renal function

Phosphorus (3.6 mg/dL)

• Normal for CKD stage 3b
• Continue monitoring as CKD progresses

Why This Patient Failed on Monotherapy

Dapagliflozin monotherapy is inappropriate for A1c 13.7% 5. Even in patients with A1c ≥10%, dapagliflozin reduced A1c by only 1.59-2.13% 5. At eGFR 32, the glucose-lowering effect is further attenuated 3, 4. This patient needed combination therapy from the outset.

Long-term Strategy

• Primary goal: Prevent progression to dialysis (current trajectory with eGFR 32)
• Secondary goal: Cardiovascular risk reduction (highest cause of mortality in this population)
• Tertiary goal: Glycemic control (important but less critical than kidney/CV protection) 9

The evidence strongly supports that kidney and cardiovascular protection take precedence over glucose lowering alone in advanced CKD 2. However, poor glycemic control (A1c >9%) accelerates kidney function decline, especially with albuminuria 9, making aggressive glucose management still essential.

Do not discontinue dapagliflozin despite reduced glucose-lowering efficacy—its kidney and cardiovascular benefits are preserved and potentially more important than its glycemic effects at this stage 1, 2.